Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

被引:35
作者
Nordin, C
Dahl, ML
Eriksson, M
Sjoberg, S
机构
[1] HUDDINGE HOSP,KAROLINSKA INST,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
[2] HUDDINGE HOSP,KAROLINSKA INST,DEPT MED,CTR METAB & ENDOCRINOL,S-14186 HUDDINGE,SWEDEN
关键词
D O I
10.1016/S0140-6736(05)66238-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:29 / 30
页数:2
相关论文
共 5 条
[1]  
DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
[2]   Cholesterol lowering and cerebrospinal fluid neurotransmitters: Increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers [J].
Eriksson, M ;
Eklundh, T ;
Sjoberg, S ;
Angelin, B ;
Nordin, C .
BIOLOGICAL PSYCHIATRY, 1996, 40 (04) :302-304
[3]   POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN [J].
MAHGOUB, A ;
IDLE, JR ;
DRING, LG ;
LANCASTER, R ;
SMITH, RL .
LANCET, 1977, 2 (8038) :584-586
[4]   CLINICAL PHARMACOKINETICS AND PRACTICAL APPLICATIONS OF SIMVASTATIN [J].
MAURO, VF .
CLINICAL PHARMACOKINETICS, 1993, 24 (03) :195-202
[5]  
VICKERS S, 1990, DRUG METAB DISPOS, V18, P138